[go: up one dir, main page]

EP2012775A1 - Utilisation de modulateurs de récepteurs aux cannabinoïdes cbx en tant que modulateurs de canaux potassium - Google Patents

Utilisation de modulateurs de récepteurs aux cannabinoïdes cbx en tant que modulateurs de canaux potassium

Info

Publication number
EP2012775A1
EP2012775A1 EP07728372A EP07728372A EP2012775A1 EP 2012775 A1 EP2012775 A1 EP 2012775A1 EP 07728372 A EP07728372 A EP 07728372A EP 07728372 A EP07728372 A EP 07728372A EP 2012775 A1 EP2012775 A1 EP 2012775A1
Authority
EP
European Patent Office
Prior art keywords
phenyl
chloro
carboxylic acid
dichloro
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07728372A
Other languages
German (de)
English (en)
Inventor
Jochen Antel
Peter-Colin Gregory
Josephus Hubertus Maria Lange
Michael Firnges
Dania Reiche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Priority to EP07728372A priority Critical patent/EP2012775A1/fr
Publication of EP2012775A1 publication Critical patent/EP2012775A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to the novel use of CB x modulators as K A TP channel modulators.
  • the present invention also relates to a method of treating, preventing, delaying progression of, delaying onset of and/or inhibiting obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans comprising administering to a subject in need thereof an effective amount of at least one CB x modulator as K A TP channel modulator.
  • Obesity according to the present invention is meant to comprise any increase in body fat that results in increased bodyweight, preferably comprising but not limited to the medical definition of obesity.
  • obesity also comprises non-medical, e.g. cosmetic overweight.
  • the invention thus also relates to non-medical weight loss, such as cosmetic weight loss and includes improving bodily appearance in general.
  • non-medical weight loss such as cosmetic weight loss and includes improving bodily appearance in general.
  • obesity is usually understood to denominate a body weight more than 20 % above the ideal body weight.
  • Even in this more narrowed sense obesity is a major health concern in Western societies. It is estimated that about 97 million adults in the United States are overweight or obese.
  • Obesity is largely the result of a positive energy balance as a consequence of increased ratio of caloric intake to energy expenditure.
  • the molecular factors regulating food intake and body weight are incompletely understood, but several genetic factors have been identified.
  • Obesity causes or exacerbates many health problems, both independently and in association with other diseases.
  • the medical problems associated with obesity which can be serious and life-threatening, generally include hypertension; type Il diabetes mellitus; elevated plasma insulin concentrations; insulin resistance; dyslipidemias; hyperlipidemia; endometrial, breast, prostate and colon cancer; osteoarthritis; respiratory complications, such as obstructive sleep apnea; cholelithiasis; gallstones; arteriosclerosis; heart disease; abnormal heart rhythms; and heart arrythmias.
  • Obesity is further associated with premature death and with a significant increase in mortality and morbidity from stroke, myocardial infarction, congestive heart failure, coronary heart disease, and sudden death.
  • Obesity is often treated by encouraging patients to lose weight by reducing their food intake or by increasing their exercise level and therefore increasing their energy output.
  • a sustained weight loss of 5% to 10% of body weight has been shown to improve the co-morbidities associated with obesity, such as diabetes and hypertension, and can lead to improvement of obesity-related conditions such as osteoarthritis, sleep apnea and pulmonary and cardiac dysfunction.
  • Weight loss drugs that are currently used in monotherapy for the treatment of obesity have limited efficacy and significant side effects. During chronic treatment periods of greater than six months the efficacy of most agents decreases yielding no more than 10% body weight loss compared to control. Obese humans can easily mass over 150 kg and would, therefore, need to lose more than 50% of their body mass to return to a normal body mass.
  • the term "metabolic syndrome” is meant to cover a complex of clinical pictures which - besides central obesity - mainly comprises hypertension, in particular arterial hypertension; insulin resistance, in particular type Il diabetes; glucose intolerance; dyslipoproteinaemia, in particular as hypertriglyceridaemia, accompanied by dyslipoproteinaemia occurring with lowered HDL-cholesterol, and also hyperuricaemia, which can lead to gout.
  • the metabolic syndrome is closely linked to insulin resistance. Some people are genetically predisposed to insulin resistance. Acquired factors, such as excess body fat and physical inactivity, can elicit insulin resistance and the metabolic syndrome in these people. Most people with insulin resistance have central obesity.
  • the biologic mechanisms at the molecular level between insulin resistance and metabolic risk factors are not fully understood and appear to be complex.
  • One group of people at risk for developing metabolic syndrome is those with diabetes who have a defect in insulin action and cannot maintain a proper level of glucose in their blood.
  • a third group is heart attack survivors who, unlike hypertensives, have hyperinsulinemia without having abnormal glucose levels.
  • the metabolic syndrome has become increasingly common in higher developed countries like the United States, where it is estimated that about 20-25 percent of US adults have it. There are no well-accepted criteria for diagnosing the metabolic syndrome.
  • the term “syndrome X” is closely related to the term “metabolic syndrome” and usually is supposed to denominate the identical disease or condition. According to information from the American Heart Association, the term “Syndrome X” refers, however, additionally to a heart condition where chest pain and electrocardiographic changes that suggest ischemic heart disease are present, but where there are no angiographic findings of coronary disease. Patients with cardiac syndrome X also sometimes have lipid abnormalities.
  • ATP-sensitive potassium channel (K A TP channel) modulation has been linked to several potential clinical uses including diabetes, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, hypertension, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence (ref. Jahangir et al. J. MoI. Cell. Cardiology, 2005, 39, 99-1 12 and references cited therein).
  • K A TP channel openers and their potential use in the inhibition of insulin secretion and/or the treatment of metabolic disorders are known e.g. from documents US 6,492,130; WO 02/00223; WO 02/00665 or from R. D. Carr et al., Diabetes 52 (2003) 2513-2518 or J. B. Hansen et al., Current Medicinal Chemistry H (2004) 1595-1615.
  • the K A TP channel couples glucose metabolism to insulin secretion. Defective regulation of K A TP channel activity has been reported to contribute to the etiology of type 2 diabetes (ref. Ashcroft, J. Clin. Investig. 2005, 1 15 (8), 2047-2057 and references cited therein).
  • the SUR1 regulatory subunit is in particular found in pancreas and brain (ref. Aguilar-Bryan et al., Science 1995, 268, 423-426).
  • the K A TP Kir6.2/SUR1 combination exists in the pancreas.
  • Insulin is the main hormone involved in blood glucose homeostasis. Insulin is involved in the regulation of glycaemia and as a consequence related to type I and type
  • the regulation of insulin secretion will be useful in the treatment of diseases such as diabetus mellitus type I, diabetus mellitus type II, obesity, metabolic syndrome and syndrome X.
  • the present invention relates to the use of at least one CB x modulator wherein the CB x modulator is selected from the group consisting of CB 1 agonists; CB 2 agonists; CB 2 partial agonists; CB 2 antagonists; CB 2 inverse agonists; and dually acting compounds which are both a CB 1 agonist and a CB 2 agonist; and mixtures thereof, as K A TP channel modulator for the prophylaxis, treatment, delayed progression, delayed onset and/or inhibition of obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain
  • the invention also relates to a method of treating, preventing, delaying progression of, delaying onset of and/or inhibiting obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans comprising administering to a subject in need thereof an effective amount of at least one CB x modulator wherein the CB x modulator is selected from the group consisting of CB 1 agonists; CB 2 agonists; CB 2 partial agonists; CB 2 antagonists; CB 2 inverse agonists; and dually acting compounds which are both a CB
  • the CB x modulators are used as K A TP channel modulators for the prophylaxis, treatment, delayed progression, delayed onset and/or inhibition of obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans.
  • a compound with an effect as full or partial opener at the Kir6.2/SUR1 K AT p channel is understood to be selective if its IC 50 value at the Kir6.2/SUR1 K AT p channel, as measured in the aforementioned binding test, is less than half, more preferred only a quarter, of the IC 50 value of that same compound at the Kir6.2/SUR2 K ATP channel.
  • Preferred CB x modulators are compounds which have effects as modulators at the Kir6.2/SUR1 K AT p channel, at the Kir6.2/SUR2B K ATP channel, the Kir6.1/ SUR2B K ATP channel, and/or at the Kir6.2/SUR2A K ATP channel.
  • the K AT p channel modulator is a K AT p channel opener.
  • CB x modulator which are suitable for use as K AT p channel modulator in the sense of the present invention are selected from, but not limited to the group consisting of: 3- (i .i-dimethyl-butyO- ⁇ . ⁇ . ⁇ -trimethyl- ⁇ aJ.I O.I Oa-tetrahydro- ⁇ H-benzoIclchromene; N- Adamantyl-4-pentyl-5-phenyl-thiazole-2-carboxamide; N- ⁇ 1 ,3,3-Trimethyl-endo-(1 S)- bicyclo[2.2.1 ]hept-2-yl ⁇ -1 -[1 -(4-methyl)-benzyl-5-(4-chloro-3-methyl-phenyl)-1 H-pyrazol- 3-carboxamide; (2-lodo-5-nitro-phenyl)-[1-(1-methyl-piperidin-2-ylmethyl)-1 H-indol-3- yl]-methanone; ⁇ 4-[
  • CB x modulator which are suitable for use as K A TP channel modulator in the sense of the present invention are selected from the group consisting of: 3-(1 ,1-dimethyl-butyl)-6,6,9-trimethyl- 6a, 7, 10, 10a-tetrahydro-6H-benzo[c]chromene; N-Adamantyl-4-pentyl-5-phenyl- thiazole-2-carboxamide; N- ⁇ 1 ,3,3-Trimethyl-endo-(1 S)-bicyclo[2.2.1]hept-2-yl ⁇ -1-[1-(4- methyl)-benzyl-5-(4-chloro-3-methyl-phenyl)-1 H-pyrazol-3-carboxamide; (2-lodo-5- nitro-phenyl)-[1-(1-methyl-piperidin-2-ylmethyl)-1 H-indol-3-yl]-methanone; ⁇ 4-[4-(
  • Noladineether 4,4,4-Trifluoro-butane-1-sulfinic acid 3-(2-hydroxymethyl-indan-4-yloxy)- phenyl ester, compound with form aldehyde; 7-Methoxy-2-oxo-8-pentyloxy-1 ,2-dihydro- quinoline-3-carboxylic acid (benzo[1 ,3]dioxol-5-ylmethyl)-amide; N-(1- ⁇ 4-[4-Chloro-2-(2- fluoro-benzenesulfonyl)-benzenesulfonyl]-phenyl ⁇ -ethyl)-methanesulfonamide; [6-lodo- 2-methyl-1-(2-morpholin-4-yl-ethyl)-2,3-dihydro-1 H-indol-3-yl]-(4-methoxy-phenyl)- methanone; 1-(4-Chloro-phenyl)
  • CB x modulator which are suitable for use as K A TP channel modulator in the sense of the present invention are selected from the group consisting of: 4-Chloro-N- ⁇ [3-(4-chloro-phenyl)-4-phenyl-4,5- dihydro-pyrazol-1 -yl]-methylamino-methylene ⁇ -benzenesulfonamide; N- ⁇ Amino-[3-(4- chloro-phenyl ⁇ -phenyM. ⁇ -dihydro-pyrazol-i-ylJ-methylene ⁇ -chloro- benzenesulfonamide; 4-Chloro-N- ⁇ [3-(4-chloro-phenyl)-4-pyridin-3-yl-4,5-dihydro- pyrazol-1-yl]-methylamino-methylene ⁇ -benzenesulfonamide; 4-Chloro-N- ⁇ [3-(4-chloro- phenyl)
  • CB 1 agonist or CB 2 agonists which are suitable for use as K A TP channel modulator in the sense of the present invention are selected from, but not limited to the group consisting of: L759633; L759656; ⁇ 4-[4-(1 ,1-dimethyl-heptyl)-2,6-dimethoxy-phenyl]-
  • the CB 2 agonist is a selective
  • the CB x modulator is selected from the group consisting of: 6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro- 6H-benzo[c]chromen-1-ol; (bicyclo[2.2.1]hept-2-ylamino)-(5-pentyl-4-phenyl-thiazol-2- yl)-methane; 3-(1 , 1 -dimethyl-butyl)-6,6,9-trimethyl-6a,7, 10,10a-tetrahydro-6H- benzo[c]chromene; N-adamantyl-4-pentyl-5-phenyl-thiazole-2-carboxamide; SR144528; (2-iodo-5-nitro-phenyl)-[1-(1-methyl-piperidin-2-ylmethyl)-1 H-indol-3-yl]-methanone; ⁇ 4- [4-(1.i
  • Table 1 also lists the CB 1 and/or CB2 activities of various compounds to prove that their activity as CB 1 agonists, CB 2 agonists, CB 2 partial agonists, CB 2 antagonists, CB 2 inverse agonists and dually acting compounds which are both a CB 1 agonist and a CB 2 agonist.
  • Membranes from COS-cells transiently expressing rat SUR2A were incubated in the presence of the radioligands with increasing concentrations of test compounds as described above. The affinity for binding to the KCO site was assessed by incubations in the additional presence of 100 ⁇ M MgATP (Schwanstecher et al., 1991 and 1998). For each test compound 4 displacement curves were measured (displacement of [ 3 H]PI 075 from the rat isoform of the wild type receptor and displacement of [ 3 H]glibenclamide from the rat isoform of SUR2A Y1205 s)- Per curve 9-15 distinct concentrations were tested covering the relevant range. All measurements were repeated at least 5 times in independent experiments.
  • [ 3 H]P1075 (specific activity 1 16 Ci mmol '1 ) was purchased from Amersham Buchler (Braunschweig, Germany).
  • [ 3 H]glibenclamide (specific activity 51 Ci mmol '1 ) was obtained from NEN (Dreieich, Germany). If suitable, stock solutions were prepared in dimethylsulfoxide with a final solvent concentration in the media below 1 %.
  • Rodent SUR-isoforms and K A TP channels were transiently expressed in COS-1 cells as described (see Schwanstecher et al., 1998); D ⁇ rschner et al., 1999); Uhde I. et al. J Biol Chem 274 (1999) 28079-28082; Gross I. et al. MoI. Pharmacol. 56 (1999) 1370-1373; Markworth E., Diabetes 49 (2000) 1413-1418).
  • SUR2 Y1205 s A mutated form of the SUR2 isoforms with the phenylalanine residue in position 1205 substituted with a serine (SUR2 Y1205 s) was used to allow detection of binding to the sulfonylurea site of these isoforms by displacement of [ 3 H]glibenclamide (Uhde I., Dissertation 2001 ). Briefly, COS-1 cells cultured in DMEM HG (10 mM glucose), supplemented with 10 % fetal calf serum (FCS), were plated at a density of 5 x 10 5 cells per dish (94 mm) and allowed to attach overnight.
  • FCS % fetal calf serum
  • ATP 0.1 mM
  • KCO e.g. diazoxide, [ 3 H]PI 075
  • Incubations were carried out for 1 h at room temperature and were terminated by rapid filtration through Whatman GF/B filters.
  • the inhibition constant (Ki value) of the test substances was calculated from the respective IC50 value, and was stated as the negative logarithmic value thereof (pK).
  • the affinity of the compounds of the invention for cannabinoid CB 1 receptors can be determined using membrane preparations of Chinese hamster ovary (CHO) cells in which the human cannabinoid CB 1 receptor is stably transfected in conjunction with [ 3 H]CP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [ 3 H]-ligand, with or without addition of compounds of the invention, separation of bound and free ligand is performed by filtration over glassfiber filters. Radioactivity on the filter is measured by liquid scintillation counting.
  • CHO Chinese hamster ovary
  • the affinity of the compounds of the invention for cannabinoid CB 2 receptors can be determined using membrane preparations of Chinese hamster ovary (CHO) cells in which the human cannabinoid CB 2 receptor is stably transfected in conjunction with [ 3 H]CP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [ 3 H]-ligand, with or without addition of compounds of the invention, separation of bound and free ligand is performed by filtration over glassfiber filters. Radioactivity on the filter is measured by liquid scintillation counting.
  • CHO Chinese hamster ovary
  • mice Male Wistar rats in the weight range 175-200 g were group housed in standard animal cages at a temperature of 21 ⁇ 2°C and humidity of 55 ⁇ 10%. Animals were maintained on a 12 h light-dark cycle (lights on 06.00-18.00 h) with free access to standard rodent diet (B&K Universal Ltd standard rat and mouse diet (BK 001 P), Beekay Feeds, B&K Universal Ltd, Hull, East Riding of Yorkshire) and tap water. The rats were accustomed to these conditions for at least one week before experimentation.
  • Perifusate samples were then pooled to create three samples per chamber as follows: Baseline (4mM): Samples 1-5 (first 10 minutes); 0-30 minutes (1 1 mM glucose): Samples 6-21 ; 30-60 minutes (1 1 mM glucose): Samples 22-36. Perifusate fractions were stored at -75°C until required for insulin assay. Insulin content of fractions were assayed using a 96-well ELISA assay (Mercodia). Initial insulin assays were performed in triplicate on three pooled fractions from each chamber.
  • the three islet preparations showed a consistent degree of glucose dependent insulin secretion.
  • the mean insulin secretion at 1 1 mM glucose was 98.3 ⁇ 12.6 pg/islet/min and 130.4 ⁇ 22.0 pg/islet/min at 0-30 and 30-60 minutes, respectively.
  • insulin secretion was increased by 26 times and 38 times by 11 mM glucose at 0-30 and 30-60 minutes, respectively.
  • the amount of broadening from the strict numerical boundary depends upon many factors. For example, some of the factors which may be considered include the criticality of the element and/or the effect a given amount of variation will have on the performance of the claimed subject matter, as well as other considerations known to those of skill in the art. As used herein, the use of differing amounts of significant digits for different numerical values is not meant to limit how the use of the words “about” or “approximately” will serve to broaden a particular numerical value. Thus, as a general matter, "about” or “approximately” broaden the numerical value.
  • ranges is intended as a continuous range including every value between the minimum and maximum values plus the broadening of the range afforded by the use of the term "about” or “approximately.”
  • ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it there individually recited herein. It is to be understood that any ranges, ratios and ranges of ratios that can be formed by, or derived from, any of the data disclosed herein represent further embodiments of the present disclosure and are included as part of the disclosure as though they were explicitly set forth.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'au moins un modulateur de CBx choisi dans le groupe composé d'agonistes de CB1, d'agonistes de CB2, d'agonistes partiels de CB2, d'antagonistes de CB2, d'agonistes inverses de CB2, et de composés à effet double étant des d'agonistes de CB1 et des agonistes de CB2, et de mélanges de ceux-ci, en tant que modulateur de canal KATP destiné à la prophylaxie, au traitement, au retardement de la progression, au retardement du déclenchement et/ou à l'inhibition d'une pluralité de troubles tels que l'obésité, le diabète sucré, le syndrome métabolique, le syndrome X, l'insulinome, l'hypoglycémie hyperinsulémique familiale, l'alopécie androgénétique, l'hyperréactivité du détrusor, l'asthme, la neuroprotection, l'épilepsie, l'analgésie, la cardioprotection, l'angine de poitrine, la cardioplégie, l'arythmie, les spasmes coronariens, les maladies vasculaires périphériques, les vasospasmes cérébraux, la régulation de l'appétit, la neurodégénération, les douleurs telles que les douleurs neuropathiques et chroniques, et l'impuissance chez l'homme et les mammifères. L'invention concerne également des procédés de traitement, de prévention, de retardement de la progression, de retardement du déclenchement et/ou d'inhibition d'une pluralité de troubles tels que l'obésité, le diabète sucré, le syndrome métabolique, le syndrome X, l'insulinome, l'hypoglycémie hyperinsulémique familiale, l'alopécie androgénétique, l'hyperréactivité du détrusor, l'asthme, la neuroprotection, l'épilepsie, l'analgésie, la cardioprotection, l'angine de poitrine, la cardioplégie, l'arythmie, les spasmes coronariens, les maladies vasculaires périphériques, les vasospasmes cérébraux, la régulation de l'appétit, la neurodégénération, les douleurs telles que les douleurs neuropathiques et chroniques, et l'impuissance chez l'homme et les mammifères, par administration d'une quantité efficace d'au moins un modulateur de CBX ayant des propriétés de modulation de canal KATP, à un sujet nécessitant un tel traitement.
EP07728372A 2006-04-27 2007-04-20 Utilisation de modulateurs de récepteurs aux cannabinoïdes cbx en tant que modulateurs de canaux potassium Withdrawn EP2012775A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07728372A EP2012775A1 (fr) 2006-04-27 2007-04-20 Utilisation de modulateurs de récepteurs aux cannabinoïdes cbx en tant que modulateurs de canaux potassium

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06113190 2006-04-27
PCT/EP2007/053915 WO2007125049A1 (fr) 2006-04-27 2007-04-20 Utilisation de modulateurs de récepteurs aux cannabinoïdes cbx en tant que modulateurs de canaux potassium
EP07728372A EP2012775A1 (fr) 2006-04-27 2007-04-20 Utilisation de modulateurs de récepteurs aux cannabinoïdes cbx en tant que modulateurs de canaux potassium

Publications (1)

Publication Number Publication Date
EP2012775A1 true EP2012775A1 (fr) 2009-01-14

Family

ID=36808728

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07728372A Withdrawn EP2012775A1 (fr) 2006-04-27 2007-04-20 Utilisation de modulateurs de récepteurs aux cannabinoïdes cbx en tant que modulateurs de canaux potassium

Country Status (10)

Country Link
EP (1) EP2012775A1 (fr)
JP (1) JP2009534440A (fr)
CN (1) CN101431994A (fr)
AR (1) AR060626A1 (fr)
AU (1) AU2007245734A1 (fr)
CA (1) CA2650567A1 (fr)
MX (1) MX2008013285A (fr)
RU (1) RU2008146591A (fr)
TW (1) TW200812576A (fr)
WO (1) WO2007125049A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
JP5946192B2 (ja) * 2010-11-18 2016-07-05 ジェンリン ディスカバリーＪｅｎｒｉｎ Ｄｉｓｃｏｖｅｒｙ 肥満症及び糖尿病を含む代謝性疾患の処置に有用なカンナビノイド受容体拮抗薬／逆作動薬
PH12014500561A1 (en) * 2011-09-29 2022-12-02 Ono Pharmaceutical Co Phenyl derivative
BR112014029868A2 (pt) 2012-05-31 2017-06-27 Phenex Pharmaceuticals Ag compostos, e, composição farmacêutica
JP6245255B2 (ja) 2013-03-26 2017-12-13 小野薬品工業株式会社 フェニル誘導体
CN106138053B (zh) * 2015-04-28 2019-04-09 上海市同济医院 一种化合物在制备治疗帕金森病的药物中的应用
EP3109237A1 (fr) 2015-06-22 2016-12-28 AnaMar AB Nouveaux antagonistes de 5-ht2
WO2021087127A1 (fr) * 2019-10-29 2021-05-06 Corbus Pharmaceuticals, Inc. Cannabinoïdes et utilisations associées
WO2025103493A1 (fr) * 2023-11-16 2025-05-22 西藏海思科制药有限公司 Antagoniste du récepteur cannabinoïde 1 et son utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1469842A4 (fr) * 2002-01-31 2006-04-26 Pharmos Corp Ligands du recepteur cannabinoide cb2 bicyclique
GB0402356D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007125049A1 *

Also Published As

Publication number Publication date
CA2650567A1 (fr) 2007-11-08
CN101431994A (zh) 2009-05-13
MX2008013285A (es) 2008-10-24
TW200812576A (en) 2008-03-16
AR060626A1 (es) 2008-07-02
JP2009534440A (ja) 2009-09-24
RU2008146591A (ru) 2010-06-10
WO2007125049A1 (fr) 2007-11-08
AU2007245734A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
US7763607B2 (en) Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
EP2012775A1 (fr) Utilisation de modulateurs de récepteurs aux cannabinoïdes cbx en tant que modulateurs de canaux potassium
US8058264B2 (en) Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions
US20070254863A1 (en) Use of CBx cannabinoid receptor modulators as potassium channel modulators
KR101387910B1 (ko) 당뇨병, 대사 증후군 및 다른 질환을 치료하기 위한 방법및 조성물
AU2007213069B2 (en) Combination of organic compounds
EP2026798A1 (fr) Compositions pharmaceutiques contenant des modulateurs de récepteurs aux cannabinoïdes cbx et des modulateurs de canaux potassium
CA2609783A1 (fr) Polytherapie pour le traitement de l'obesite ou le maintien du poids apres une perte ponderale
US20090075974A1 (en) Agent for prophylaxis and treatment of pancreatitis
JP2009501192A (ja) 有機化合物の組み合わせ
HK1128228A (en) Use of cbx cannabinoid receptor modulators as potassium channel modulators
HK1128229A (en) Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators
EP1583535A2 (fr) Méthodes de traitement du diab te
Slassi et al. Novel serotonergic and non-serotonergic migraine headache therapies
HUP0001889A2 (hu) COX-2 inhibitort és 5HT1-receptor antagonista hatású vegyületet tartalmazó kombinált gyógyszerkészítmények migrén kezelésére
KR20070070226A (ko) 타입 ⅰ 당뇨, 비만 및 관련된 증상의 치료를 위한 ｃｂ１칸나비노이드 수용체 길항제 및 포타슘 채널 오프너를포함하는 약학적 조성물
WO2004098641A2 (fr) Composition pharmaceutique pour traiter l'obesite ou bien faciliter ou favoriser la perte de poids
HK1106449A (en) Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101102